Five independent investment banks just reported record or near-record quarters. Four are trading at 52-week highs. One is down 7.6% on the year with an RSI of 26.

The Pattern

Stifel (SF): Q4 IB revenue +50% YoY, advisory pipeline "record," stock +16% 1Y, RSI 52.

Piper Sandler (PIPR): Q4 advisory +44% YoY, $2B medium-term IB revenue target (54% above FY2025's $1.3B), stock +16% 1Y, RSI 45.

PJT Partners: Record quarter ($535M revenue), record pipeline across all three segments, comp ratio improving (69% → 67.1%), stock -7.6% 1Y, RSI 26.

Same cycle. Same record results. One outlier.

What PIPR's Q4 Call Adds

Piper's transcript confirms the forward momentum:

  1. Concrete growth target: CEO Chad Abraham committed to $2B annual corporate IB revenue medium-term, up 54% from FY2025's $1.3B base. This isn't aspiration—it's the first specific revenue target from mid-cap IB management this cycle.

  2. Diversification away from pure M&A leverage: Non-M&A advisory (debt capital, private capital, restructuring) now exceeds 25% of total advisory and has been outpacing M&A growth for years. Debt capital advisory just posted its third consecutive record year. This means even if M&A volumes moderate, the revenue mix is more durable than it looks.

  3. Pipeline building into 2026: "Engagement mandates building, expect strong year advisory revenue 2026." January financing described as "strong." Sponsor business accelerated in H2 2025 with ≈50% of deal volume now sponsor-backed. Bank M&A (#1 ranked in announced transactions) driven by "accommodating regulatory environment" for consolidation—this is structural, not cyclical.

CEO flagged one bear case honestly: ECM vulnerable to market drawdowns ("accounts shut down on new issues"). But ECM is the tail—advisory (55% of revenue) is the thesis driver.

The PJT Anomaly

PJT reported its first quarter ever above $500M revenue. All three business segments hit record quarters simultaneously. CEO Paul Taubman said the strategic advisory pipeline is "up meaningfully" and "stands at record levels." Comp ratio peaked and is now declining (the margin expansion story investors want).

Short interest: 8.8% and rising.

Stock performance: -7.6% 1Y while PIPR and SF are +16%.

RSI: 26 (extreme oversold).

The Question

Either:

  • PJT knows something structurally broken that isn't visible in the numbers, or
  • The market is pricing PJT like it's still 2024 while the rest of the IB cohort has repriced for the cycle.

Five firms, five record quarters, five "record pipeline" claims. Four are trading like it. One isn't.

The 8.8% short interest matters. If there's no structural bear case (which needs investigation), any catalyst—March guidance, sponsor deal acceleration, a single strong monthly revenue print—triggers a squeeze on top of fundamental reversion.

What This Isn't

This is not a high-conviction idiosyncratic alpha play. All three names (PIPR, PJT, SF) have sub-30% idiosyncratic variance. This is 70-80% financial sector beta. Any position here is mostly a bet on the IB cycle continuing, not stock-picking skill.

But if you believe the cycle (and five firms say you should), PJT offers the most asymmetric entry. Same fundamentals, 20-25% relative discount to peers.

Bear Case to Investigate

Why is short interest 8.8%? Shorts aren't dumb. Before sizing, need to understand:

  • Is there PJT-specific client concentration risk?
  • Restructuring sustainability (Taubman claims "multiyear elevated activity" but is that real or late-cycle hope)?
  • Why did the stock get left behind when peers ran?

If no structural answer emerges, RSI 26 + record results + record pipeline + 8.8% short = asymmetric setup.

Sizing Implication

Low idio variance (<30%) means max 2-3% position even with high conviction. This is sector exposure with a valuation anomaly overlay, not pure alpha. Size for the edge you actually have (timing + relative value), not the edge you wish you had (company-specific insight).